JPMorgan & LPL Financial Ink Municipal Bond Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 5:20PM CST
JPMorgan (JPM), the largest bank in the U.S., announced a municipal bond deal with LPL Financial LLC, the wholly owned subsidiary of LPL Financial Holdings (LPLA).
JPM: 58.43 (-0.73), EBSB: 11.01 (unch), BANF: 62.65 (+0.45), LPLA: 42.26 (+0.81)
Wells Fargo Sets Up Cleantech Innovation Incubator Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 6:20PM CDT
Wells Fargo (WFC), in a first ever kind of initiative in the banking domain, launched the Innovation Incubator program
WAL: 26.30 (+0.15), EBSB: 11.01 (unch), WFC: 52.77 (-0.42), GSBC: 36.22 (-0.05)
Meridian Interstate beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 5:02PM CDT
EBSB: 11.01 (unch)
Meridian Bancorp, Inc. Reports Net Income for the Third Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Tue Oct 28, 3:10PM CDT
Meridian Bancorp, Inc. (the "Company" or "Meridian"
EBSB: 11.01 (unch)
Washington Federal Beats on Q3 Earnings, Shares Dip 1% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 2:50PM CDT
Washington Federal's (WAFD) shares fell nearly 1% in two days trading, following the release of its 2014 fiscal year-end earnings (ended Sep 30) on Oct 22, before the market opened.
TLMR: 13.86 (-0.08), EBSB: 11.01 (unch), SLCT: 7.40 (+0.27), WAFD: 21.71 (+0.06)
People's United Reports In-Line Q3 Earnings, Revenues Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 11:00AM CDT
People's United's (PBCT) third-quarter 2014 operating earnings of 21 cents per share came in line with the Zacks Consensus Estimate.
PBCT: 14.51 (+0.02), LPSB: 12.28 (-0.23), NFBK: 14.23 (+0.17), EBSB: 11.01 (unch)
Why the Earnings Streak Will Continue for Meridian Bancorp (EBSB) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 7:42AM CDT
Meridian Bancorp could be a great candidate for another beat after a solid performance in the last two quarters.
EBSB: 11.01 (unch)
Meridian Bancorp (EBSB) Upgraded to Strong Buy on Conversion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:50PM CDT
On Sep 27, Zacks Investment Research upgraded Meridian Bancorp, Inc. (EBSB) to a Zacks Rank #1 (Strong Buy).
LPSB: 12.28 (-0.23), EBSB: 11.01 (unch), GSBC: 36.22 (-0.05), SLCT: 7.40 (+0.27)
Why Meridian Bancorp (EBSB) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 7:54AM CDT
Meridian Bancorp is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
EBSB: 11.01 (unch)
Technical Notes Covering Financials Sector Equities - BGC Partners, UBS AG, MGIC Investment, Meridian Bancorp, and Radian
PR Newswire - Mon Sep 15, 7:45AM CDT
The US markets on Friday, September 12, 2014, ended on a lower note as the Dow Jones Industrial Average finished at 16,987.51, down 0.36% and the NASDAQ Composite closed at 4,567.60, down 0.53%. The S&P 500 finished the session 0.60% lower at 1,985.54. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Financials Sector Index ended the day at 314.10, down 0.12%, whereas the index has advanced 3.36% in the previous three months. Investor-Edge has initiated coverage on the following equities: BGC Partners Inc. (NASDAQ: BGCP), UBS AG (NYSE: UBS), MGIC Investment Corporation (NYSE: MTG), Meridian Bancorp Inc. (NASDAQ: EBSB), and Radian Group Inc. (NYSE: RDN). Free research on these five companies can be accessed at:
RDN: 16.29 (-0.24), EBSB: 11.01 (unch), UBS: 17.22 (+0.04), MTG: 8.75 (-0.19), BGCP: 8.54 (+0.07)
Meridian Bancorp, Inc. Announces Closing of Stock Offering and Completion of Conversion Transaction
GlobeNewswire - Mon Jul 28, 4:30PM CDT
Meridian Bancorp, Inc. (the "Company"
EBSB: 11.01 (unch)
Meridian Interstate Bancorp, Inc. Announces Stock Offering Results and Expected Closing Date
GlobeNewswire - Thu Jul 24, 3:18PM CDT
Meridian Interstate Bancorp, Inc. (the "Company"
EBSB: 11.01 (unch)
Meridian Interstate Bancorp, Inc. Reports Net Income for the Second Quarter and Six Months Ended June 30, 2014
GlobeNewswire - Tue Jul 22, 3:11PM CDT
Meridian Interstate Bancorp, Inc. (the "Company" or "Meridian"
EBSB: 11.01 (unch)
Upgrade Alert for Meridian Interstate Bancorp (EBSB)
Comtex SmarTrend(R) - Tue Jul 15, 7:01AM CDT
Meridian Interstate Bancorp (NASDAQ:EBSB) was upgraded from Neutral to Buy at Compass Point today. The stock closed yesterday at $25.29 on volume of 50,000 shares, above average daily volume of 30,000. Meridian Interstate Bancorp, Inc. is the holding company for East Boston Savings Bank.
EBSB: 11.01 (unch)
Meridian Bancorp, Inc. Completes Syndicated Community Offering
GlobeNewswire - Mon Jul 14, 5:00AM CDT
Meridian Interstate Bancorp, Inc. (the "Company"
EBSB: 11.01 (unch)
Meridian Bancorp, Inc. Commences Syndicated Community Offering and Announces Preliminary Results of Subscription and Community Offering
GlobeNewswire - Mon Jul 07, 3:15PM CDT
Meridian Interstate Bancorp, Inc. (the "Company"
EBSB: 11.01 (unch)
Meridian Bancorp, Inc. to Increase Purchase Limitations
GlobeNewswire - Tue Jun 24, 3:30PM CDT
Meridian Interstate Bancorp, Inc. (the "Company"
EBSB: 11.01 (unch)
Semi-Annual Changes to the NASDAQ OMX ABA Community Bank Index
GlobeNewswire - Mon Jun 16, 6:09AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the semi-annual evaluation of the NASDAQ OMX ABA Community Bank Index (Nasdaq:ABQI), which will become effective prior to market open on Monday, June 23, 2014.
SNBC: 19.41 (+0.13), FBNK: 15.94 (+0.27), BOKF: 58.25 (+0.34), MBVT: 28.55 (+0.06), PGC: 17.42 (+0.17), BPOP: 31.56 (-0.28), HBNC: 24.84 (+0.10), EBSB: 11.01 (unch), FBNC: 17.37 (+0.32), BBNK: 23.21 (+0.62), OABC: 25.86 (-0.37), PSTB: 6.88 (+0.09), PFBC: 25.40 (+0.29), CNBC: 19.23 (unch), BNCN: 16.41 (+0.03), WSBF: 12.31 (-0.08), BSRR: 15.92 (+0.02), PCBK: 13.55 (+0.01), NDAQ: 45.74 (-0.72), CSBK: 13.15 (+0.06), KRNY: 13.86 (+0.27)
2013 Report on Global Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
M2 - Wed Jan 22, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/x9nmsl/opportunityanalyze) has announced the addition of the "2013 Report on Global Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017" report to their offering. Cystic Fibrosis is caused by a genetic mutation which leads to the production of thickened sticky secretions in organs with epithelial cell linings, including the respiratory tract. Over time, lung infections lead to airway destruction, respiratory failure and death. The first-in-class CFTR modulator Kalydeco, a CFTR potentiator works to restore the function of the mutated CFTR protein in patients with the G551D gating mutation of CF, allowing an improved flow of salt and fluids on the surface of the lungs. Only around 4% of CF patients in the US have the G551D gating mutation, and more studies are needed to help determine whether people with other CF gating mutations might also be eligible for Kalydeco. Still, the drug's approval has paved the way for a new class of therapies, which offer a personalized treatment approach to patients and could be highly profitable for its developers. Vertex is now developing a combination therapy of potential first-in-class CFTR modulator lumacaftor (VX-809) with Kalydeco (VX-770) for the treatment of CF patients who are homozygous for the F508del mutation in the CFTR gene. The CFTR corrector, lumacaftor increases trafficking of the defective CFTR protein to the cell membrane, where it can exert its functions. The combination therapy is currently in Phase III stage of development, and is expected to gain approval in 2014. It is estimated that around half of all CF patients are homozygous to the F508del mutation, and Vertex has also announced plans to explore the lumacaftor/Kalydeco combination therapy in patients that are heterozygous to the F508del mutation. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Oppportunity Analysis 7 R&D Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/x9...ityanalyze
EBSB: 11.01 (unch), NBTB: 24.95 (+0.45)